SG Americas Securities LLC Raises Position in Certara, Inc. (NASDAQ:CERT)

SG Americas Securities LLC increased its position in shares of Certara, Inc. (NASDAQ:CERT) by 24.2% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 20,260 shares of the company’s stock after purchasing an additional 3,948 shares during the period. SG Americas Securities LLC’s holdings in Certara were worth $237,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. Wasatch Advisors LP lifted its holdings in Certara by 23.4% during the first quarter. Wasatch Advisors LP now owns 4,924,845 shares of the company’s stock worth $88,056,000 after buying an additional 932,598 shares during the period. Daventry Group LP lifted its stake in shares of Certara by 153.0% during the second quarter. Daventry Group LP now owns 1,308,572 shares of the company’s stock worth $18,124,000 after buying an additional 791,405 shares during the period. Geneva Capital Management LLC boosted its position in Certara by 15.1% in the first quarter. Geneva Capital Management LLC now owns 4,404,199 shares of the company’s stock valued at $78,747,000 after buying an additional 579,349 shares during the last quarter. Sei Investments Co. boosted its holdings in shares of Certara by 39.5% in the 2nd quarter. Sei Investments Co. now owns 997,871 shares of the company’s stock valued at $13,821,000 after acquiring an additional 282,357 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in shares of Certara by 9.7% in the second quarter. Dimensional Fund Advisors LP now owns 3,079,023 shares of the company’s stock worth $42,643,000 after acquiring an additional 273,095 shares during the period. Hedge funds and other institutional investors own 73.96% of the company’s stock.

Insider Buying and Selling

In other Certara news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th. The shares were sold at an average price of $11.29, for a total transaction of $578,318.96. Following the sale, the insider now owns 99,704 shares of the company’s stock, valued at $1,125,658.16. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, insider Leif E. Pedersen sold 51,224 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.29, for a total value of $578,318.96. Following the transaction, the insider now directly owns 99,704 shares of the company’s stock, valued at approximately $1,125,658.16. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Patrick F. Smith sold 5,409 shares of the business’s stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $11.03, for a total transaction of $59,661.27. Following the transaction, the insider now owns 50,091 shares in the company, valued at $552,503.73. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.39% of the stock is owned by company insiders.

Analyst Ratings Changes

CERT has been the topic of several analyst reports. Robert W. Baird cut their price target on Certara from $19.00 to $18.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th. UBS Group raised shares of Certara from a “neutral” rating to a “buy” rating and set a $16.00 price objective on the stock in a research note on Friday, September 27th. Barclays lowered their price target on shares of Certara from $16.00 to $14.00 and set an “equal weight” rating on the stock in a report on Tuesday, October 15th. KeyCorp decreased their price objective on shares of Certara from $23.00 to $20.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Finally, JMP Securities restated a “market perform” rating on shares of Certara in a research note on Wednesday, July 10th. Six research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $17.08.

Certara Stock Performance

CERT opened at $11.20 on Tuesday. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -28.72, a PEG ratio of 5.40 and a beta of 1.49. The firm’s fifty day simple moving average is $11.60 and its two-hundred day simple moving average is $14.33. The company has a quick ratio of 2.61, a current ratio of 2.61 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 52-week low of $10.35 and a 52-week high of $19.87.

Certara (NASDAQ:CERT) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Certara had a positive return on equity of 3.03% and a negative net margin of 21.64%. The firm had revenue of $93.31 million during the quarter, compared to analyst estimates of $96.01 million. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The company’s quarterly revenue was up 3.2% on a year-over-year basis. Equities analysts anticipate that Certara, Inc. will post 0.27 earnings per share for the current fiscal year.

Certara Profile

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.